Video

Evaluating risuteganib for dry eye disease treatment

Author(s):

David Hutton,Alex Delaney-Gesing

Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island (Garden City, NY), discusses highlights from his presentation of trial results analyzing risuteganib as a potential treatment for dry eye disease.

Read more about the trial results here

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial
June 11th 2025

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids
June 9th 2025

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis
June 8th 2025

Q&A: Jay Chhablani, MD, discusses 3D choroidal vasculature analysis

(Image credit: AdobeStock/zinkevych) FDA nod for acoltremon: What its approval means for clinicians and patients
June 7th 2025

FDA nod for acoltremon: What its approval means for clinicians and patients

© 2025 MJH Life Sciences

All rights reserved.